RNACNasdaqPharmaceutical PreparationsFiscal year ends December 31

Cartesian Therapeutics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026

$6.08−0.19 (-3.03%)

Close on Oct 19, 2026

Market cap: $181.55M
P/E (TTM): –
Dividend yield: –

Cartesian Therapeutics, Inc. income statement

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31
Revenue	2.80	39	26	111	85	17	6.68	0.90	0.21	8.08	6.01	3.04
Research & Development	58	45	71	72	69	55	43	48	45	30	23	10
General & Administrative	31	30	40	24	21	19	16	18	19	13	8.34	7.95
Operating Expenses	146	83	112	96	90	73	59	66	64	43	31	18
Operating Income	-143	-44	-86	15	-4.60	-57	-52	-65	-64	-35	-25	-15
Interest Expense	–	0	2.83	3.03	2.84	1.56	1.52	1.49	1.21	1.25	0.95	0.55
Interest & Investment Income	6.58	7.39	4.96	–	–	–	–	–	–	–	–	–
Other Non-Operating Income	3.91	-33	0.69	0.33	0.02	0.09	-1.31	0.01	-0.15	0.00	-0.03	-0.04
Merger & Restructuring Charges	0	0.80	6.43	–	–	–	–	–	–	–	–	–
Asset Impairment Charges	0	7.60	0.71	–	–	–	–	–	–	–	–	–
Gain (Loss) on Sale of Assets	0	-0.27	-0.48	0.15	0	0.05	-0.10	0.08	-0.04	0.00	0	0
Pretax Income	-139	-77	-239	35	-9.72	-69	-55	–	–	–	–	–
Income Tax Expense	-9.19	0.29	-19	-0.61	16	0	0	–	–	–	–	–
Net Income	-130	-77	-220	35	-26	-69	-55	-65	-65	-36	-25	-13
Net Income to Common	-130	-77	-257	35	-26	-69	-55	-65	-65	-41	-33	-16
EPS (Basic)(per share)	-5.02	-4.48	-49.76	7.20	-6.60	-20.40	-36.60	-87.60	-96.00	-116.70	-453.90	-235.20
EPS (Diluted)(per share)	-5.02	-4.49	-49.76	3.00	-6.60	-20.40	-36.60	-87.60	-96.00	-116.70	-453.90	-235.20
Shares Outstanding (Basic, Weighted)(shares)	26	17	5.17	4.83	3.81	3.37	1.52	0.75	0.68	0.35	0.07	0.07
Shares Outstanding (Diluted, Weighted)(shares)	26	17	5.17	4.86	3.81	3.37	1.52	0.75	0.68	0.35	0.07	0.07

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: –
Operating margin: -10518.6%
Net margin: -10283.8%
Return on equity, FY2025: 195.9%

Financial strength

Current ratio: 7.48
Debt to equity: -0.42
Debt to assets: 16.6%
Cash to current liabilities: 718.3%

Valuation

P/E ratio: –
Price to sales: 122.92
Price to book: –
Dividend yield: –